The Russian authorities have made changes to drug lists. Now pharmacies are not required to have ranitidine-based drugs available. The corresponding decree No. 2419-р dated August 24, 2022 was signed by Prime Minister Mikhail Mishustin. The document excludes this INN from the minimum assortment.
The Commission of the Ministry of Health of the Russian Federation for the formation of lists of medicines has decided to exclude Ranitidine from the lists of VED and the minimum assortment back in November 2021.
Earlier, several Russian pharmaceutical companies suspended the sale and withdrew from circulation more than two hundred series of Ranitidine, as the pharmaceutical substance was found to have an excessive level of nitrosodimethylamine (NDMA) impurity.
By order of the Ministry of Health, the use of all registered medicines with this active substance was suspended in Russia from October 2021.
Ranitidine is an anti-ulcer drug belonging to second generation H2-histamine receptor blockers. Its action is based on a decrease in the secretion of gastric juice. Ranitidine is included in the vital and essential drugs list. Many Russian and foreign manufacturers have withdrawn medicines based on this substance from the market due to excessive level of nitrosodimethylamine (NDMA) admixture.
